| Literature DB >> 29380553 |
Huanhuan Hu1, Tohru Nakagawa2, Shuichiro Yamamoto2, Toru Honda2, Hiroko Okazaki3, Akihiko Uehara4, Makoto Yamamoto5, Toshiaki Miyamoto6, Takeshi Kochi7, Masafumi Eguchi7, Taizo Murakami8, Makiko Shimizu8, Kentaro Tomita9, Satsue Nagahama10, Teppei Imai11, Akiko Nishihara11, Naoko Sasaki12, Takayuki Ogasawara12, Ai Hori13, Akiko Nanri1,14, Shamima Akter1, Keisuke Kuwahara1,15, Ikuko Kashino1, Isamu Kabe7, Tetsuya Mizoue1, Tomofumi Sone16, Seitaro Dohi3.
Abstract
AIMS/Entities:
Keywords: Japanese; Risk model; Type 2 diabetes
Mesh:
Substances:
Year: 2018 PMID: 29380553 PMCID: PMC6123034 DOI: 10.1111/jdi.12809
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Baseline characteristics of study participants in the derivation and validation cohorts, Japan Epidemiology Collaboration on Occupational Health Study, 2008–2015
| Characteristics | Derivation cohort | Validation cohort |
|
|---|---|---|---|
| No. participants | 30,500 | 15,698 | |
| Age (years) | 45.4 ± 7.7 | 45.5 ± 7.6 | 0.09 |
| Women (%) | 15.0 | 15.0 | 0.93 |
| BMI (kg/m2) | 23.3 ± 3.2 | 23.2 ± 3.2 | 0.03 |
| Waist circumference (cm) | 82.3 ± 8.8 | 82.2 ± 8.9 | 0.24 |
| Smoking status (%) | |||
| Current smoker | 36.7 | 37.3 | 0.41 |
| Past smoker | 20.6 | 20.2 | |
| Never smoker | 42.7 | 42.5 | |
| Hypertension (%) | 18.2 | 18.2 | 0.99 |
| Dyslipidemia (%) | 44.4 | 43.8 | 0.17 |
| FPG (mg/dL) | 96.5 ± 9.0 | 96.4 ± 9.0 | 0.37 |
| HbA1c (%) | 5.5 ± 0.4 | 5.5 ± 0.4 | 0.74 |
Data are mean ± standard deviation unless otherwise indicated. BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin.
Multivariate regression coefficients (standard errors) of diabetes risk prediction models in the derivation cohort, Japan Epidemiology Collaboration on Occupational Health Study, 2008–2015
| No. participants | No. cases | Non‐invasive model | Invasive model including FPG | Invasive model including HbA1c | Invasive model including FPG and HbA1c | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| β (SE) |
| β (SE) |
| β (SE) |
| β (SE) |
| |||
| Sex | ||||||||||
| Women | 4,412 | 161 | Reference | |||||||
| Men | 23,872 | 2,055 | 0.365 (0.089) | <0.01 | – | – | – | – | – | – |
| Age (years) | ||||||||||
| 30–<40 | 8,569 | 390 | Reference | Reference | Reference | Reference | ||||
| 40–<50 | 11,380 | 842 | 0.380 (0.061) | <0.01 | 0.157 (0.062) | <0.01 | 0.131 (0.062) | <0.01 | 0.063 (0.063) | <0.81 |
| 50–<60 | 8,335 | 984 | 0.961 (0.062) | <0.01 | 0.447 (0.063) | <0.01 | 0.446 (0.063) | <0.01 | 0.248 (0.063) | <0.01 |
| BMI (kg/m2) | ||||||||||
| <21 | 6,819 | 201 | Reference | Reference | Reference | Reference | ||||
| 21–<23 | 7,565 | 395 | 0.396 (0.087) | <0.01 | 0.167 (0.086) | <0.01 | 0.304 (0.088) | <0.01 | 0.121 (0.087) | 0.12 |
| 23–<25 | 6,927 | 525 | 0.677 (0.085) | <0.01 | 0.297 (0.083) | <0.01 | 0.434 (0.086) | <0.01 | 0.181 (0.084) | 0.03 |
| 25–<27 | 3,987 | 484 | 1.016 (0.092) | <0.01 | 0.525 (0.087) | <0.01 | 0.611 (0.089) | <0.01 | 0.320 (0.089) | <0.01 |
| 27–<29 | 1,819 | 274 | 1.152 (0.111) | <0.01 | 0.694 (0.098) | <0.01 | 0.694 (0.099) | <0.01 | 0.464 (0.099) | <0.01 |
| ≥29 | 1,167 | 337 | 1.715 (0.114) | <0.01 | 1.131 (0.099) | <0.01 | 1.019 (0.099) | <0.01 | 0.758 (0.101) | <0.01 |
| WC | ||||||||||
| <90 | 22,500 | 1,310 | Reference | |||||||
| ≥90 | 5,784 | 906 | 0.182 (0.065) | <0.01 | – | – | – | – | – | – |
| Smoking status | ||||||||||
| Never smoker | 12,301 | 718 | Reference | Reference | Reference | Reference | ||||
| Past smoker | 5,767 | 523 | 0.162 (0.060) | <0.01 | 0.044 (0.059) | 0.34 | 0.199 (0.059) | <0.01 | 0.074 (0.059) | 0.16 |
| Current smoker | 10,216 | 975 | 0.325 (0.051) | <0.01 | 0.356 (0.051) | <0.01 | 0.202 (0.051) | <0.01 | 0.221 (0.052) | <0.01 |
| Hypertension | ||||||||||
| No | 23,475 | 1,467 | Reference | Reference | Reference | Reference | ||||
| Yes | 4,809 | 749 | 0.471 (0.049) | <0.01 | 0.251 (0.050) | <0.01 | 0.550 (0.050) | <0.01 | 0.375 (0.051) | <0.01 |
| Dyslipidemia | ||||||||||
| No | 16,164 | 782 | Reference | Reference | Reference | |||||
| Yes | 12,120 | 1,434 | 0.325 (0.047) | <0.01 | 0.208 (0.048) | <0.01 | 0.158 (0.049) | <0.01 | ||
| FPG (mg/dL) | ||||||||||
| <100 | 19,783 | 437 | Reference | Reference | ||||||
| 100–<110 | 6,947 | 682 | 1.257 (0.063) | <0.01 | 0.937 (0.065) | <0.01 | ||||
| 110–<126 | 1,554 | 1,097 | 2.950 (0.062) | <0.01 | 2.221 (0.068) | <0.01 | ||||
| HbA1c (%) | ||||||||||
| <5.6 | 16,589 | 300 | Reference | Reference | ||||||
| 5.6–<6.0 | 10,138 | 842 | 1.348 (0.068) | <0.01 | 1.019 (0.069) | <0.01 | ||||
| 6.0–<6.5 | 1,557 | 1,074 | 3.083 (0.069) | <0.01 | 2.295 (0.076) | <0.01 | ||||
In invasive models, sex and waist circumference (WC) were not statistically significant, and thus were excluded. †WC was 80 cm for women. BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; SE, standard error.
Figure 1Receiver operating characteristic curves for each risk model in predicting 7‐year diabetes risk, Japan Epidemiology Collaboration on Occupational Health Study, 2008–2015. (a) In the derivation cohort, the area under the receiver operating characteristic curve were 0.73 (95% confidence interval [CI] 0.72–0.74) for the non‐invasive model, 0.86 (95% CI 0.85–0.87) for the model including fasting plasma glucose (FPG), 0.85 (95% CI 0.84–0.86) for the model including glycated hemoglobin (HbA1c) and 0.89 (95% CI 0.89–0.90) for the model including both FPG and HbA1c. (b) In the validation cohort, the corresponding values were 0.73 (95% CI 0.68–0.77) for the non‐invasive model, 0.86 (95% CI 0.82–0.89) for the model including FPG, 0.85 (95% CI 0.82–0.88) for the model including HbA1c and 0.90 (95% CI 0.87–0.92) for the model including both FPG and HbA1c.
Discriminative ability of invasive risk models in comparison with the non‐invasive model in the derivation and validation cohorts, Japan Epidemiology Collaboration on Occupational Health Study, 2008–2015
| NRI (95% CI) | IDI (95% CI) | |
|---|---|---|
| Derivation cohort | ||
| Non‐invasive model | Reference | Reference |
| Invasive model including HbA1c | 0.50 (0.47–0.53) | 0.17 (0.16–0.18) |
| Invasive model including FPG | 0.56 (0.53–0.59) | 0.18 (0.18–0.19) |
| Invasive model including HbA1c and FPG | 0.74 (0.71–0.77) | 0.26 (0.25–0.27) |
| Validation cohort | ||
| Non‐invasive model | Reference | Reference |
| Invasive model including HbA1c | 0.46 (0.42–0.51) | 0.16 (0.15–0.17) |
| Invasive model including FPG | 0.53 (0.49–0.59) | 0.17 (0.16–0.19) |
| Invasive model including HbA1c and FPG | 0.71 (0.66–0.76) | 0.24 (0.23–0.26) |
FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; IDI, integrated discrimination improvement; NRI, net reclassification improvement.
Figure 2Calibration plot for type 2 diabetes risk models in the derivation cohort, by deciles of predicted risk, Japan Epidemiology Collaboration on Occupational Health Study, 2008–2015. (a) Non‐invasive risk model. (b) Invasive risk model including both glycated hemoglobin and fasting plasma glucose.
Figure 3Calibration plot for type 2 diabetes risk models in the validation cohort, by deciles of predicted risk, Japan Epidemiology Collaboration on Occupational Health Study, 2008–2015. (a) Non‐invasive risk model. (b) Invasive risk model including both glycated hemoglobin and fasting plasma glucose.